Galapagos & Moderna Partner on mRNA Cystic Fibrosis Drugs
Ticker: GLPGF · Form: 6-K · Filed: Jun 17, 2024 · CIK: 1421876
| Field | Detail |
|---|---|
| Company | Galapagos NV (GLPGF) |
| Form Type | 6-K |
| Filed Date | Jun 17, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: collaboration, drug-discovery, mRNA, pharmaceuticals
Related Tickers: MRNA
TL;DR
Galapagos teams up with Moderna for new mRNA CF drugs.
AI Summary
Galapagos NV announced on June 14, 2024, that it has entered into a new collaboration with Moderna, Inc. This agreement focuses on the discovery and development of novel mRNA medicines for cystic fibrosis. The collaboration will leverage Galapagos' expertise in fibrosis and Moderna's mRNA platform technology.
Why It Matters
This partnership could lead to new therapeutic options for cystic fibrosis patients by combining Galapagos' deep understanding of the disease with Moderna's cutting-edge mRNA technology.
Risk Assessment
Risk Level: medium — Drug development is inherently risky, with high failure rates and long timelines, and the success of this collaboration is not guaranteed.
Key Players & Entities
- Galapagos NV (company) — Registrant
- Moderna, Inc. (company) — Collaboration Partner
- June 14, 2024 (date) — Announcement Date
- cystic fibrosis (disease) — Therapeutic Area
- mRNA (technology) — Platform Technology
FAQ
What is the primary focus of the new collaboration between Galapagos NV and Moderna, Inc.?
The collaboration is focused on the discovery and development of novel mRNA medicines for cystic fibrosis.
When was the press release announcing this collaboration issued?
The press release was issued on June 14, 2024.
What expertise does Galapagos NV bring to this partnership?
Galapagos NV brings its expertise in fibrosis.
What technology platform is Moderna, Inc. contributing to the collaboration?
Moderna, Inc. is contributing its mRNA platform technology.
Is this information being incorporated into any of Galapagos NV's existing registration statements?
Yes, the information contained in this Report on Form 6-K, including Exhibit 99.1, is incorporated by reference into Galapagos NV's Registration Statements on Form S-8.
Filing Stats: 220 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2024-06-17 07:38:08
Filing Documents
- f6k_061424.htm (6-K) — 4KB
- exh_991.htm (EX-99.1) — 15KB
- 0001171843-24-003460.txt ( ) — 20KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. GALAPAGOS NV (Registrant) Date: June 17, 2024 /s/ Annelies Denecker Annelies Denecker Company Secretary